PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.…
PepGen (PEPG) Stock Sees Fair Value Lift After Encouraging EDODM1 Analyst Reactions
PepGen Reports Phase 2 Myotonic Dystrophy Trial Results and $104.8 Million Cash Position
PepGen (NASDAQ: PEPG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 53 employees.
The shares were at 3.780 USD on 20 November 2026, down 18.2% over 52 weeks. Its 52-week range is 1.310 USD to 7.800 USD: the price is 51.5% below the high and 188.5% above the low.
Its market capitalisation is 356.31M USD.
PepGen reports return on equity of -60.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 89.20M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 13.75 USD is 263.8% above the current price. The next earnings report is expected on 4 March 2027.